Compare BNR & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNR | SCM |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.7M | 267.2M |
| IPO Year | 2019 | 2012 |
| Metric | BNR | SCM |
|---|---|---|
| Price | $9.02 | $8.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 10.1K | ★ 147.3K |
| Earning Date | 06-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | $111.65 | $0.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $153.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.80 | $8.43 |
| 52 Week High | $41.72 | $15.39 |
| Indicator | BNR | SCM |
|---|---|---|
| Relative Strength Index (RSI) | 20.79 | 38.40 |
| Support Level | $7.99 | $8.93 |
| Resistance Level | $9.70 | $9.85 |
| Average True Range (ATR) | 1.17 | 0.26 |
| MACD | -0.72 | -0.02 |
| Stochastic Oscillator | 2.40 | 11.23 |
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.